Viewing data from:

BLEOMYCIN SULFATE

ANDA

BLEOMYCIN SULFATE | A065031 | HOSPIRA INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$26.45

per ea

Lowest NADAC/Unit

$26.45

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
61703033218BLEOMYCIN SULFATE 15 UNIT VIAL	$26.45	EA	Generic	—	2026-04-22
00409033220BLEOMYCIN SULFATE 15 UNIT VIAL	$26.45	EA	Generic	—	2026-04-22

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVBLEOMYCIN SULFATE

DMF 137841998

ZHEJIANG HISUN PHARMACEUTICAL CO LTDBLEOMYCIN SULFATE USP (PROCESS II)

DMF 263122012

HUBEI HONCH PHARMACEUTICAL CO LTDBLEOMYCIN SULFATE

DMF 426292025

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveBLEOMYCIN SULFATE USP

DMF 129621998

MAYNE PHARMA USA INCInactiveBLEOMYCIN SULFATE

DMF 132541998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 10, 2000	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 15 UNITS BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Mar 10, 2000

No patent or exclusivity listings for this strength.

#002 — EQ 30 UNITS BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Mar 10, 2000